Applied DNA Reports Fiscal Third Quarter 2017 Financial Results Company to Hold Conference Call and Webcast Today at 4:30 PM Eastern Time

Applied DNA Reports Fiscal Third Quarter

2017 Financial Results

to Hold Conference Call and Webcast Today at 4:30 PM Eastern Time

STONY BROOK, N.Y., August 10, 2017 - Applied DNA Sciences,

Inc. (NASDAQ: APDN) ("Applied DNA", or "the Company"), announced financial results for the fiscal 2017 third

quarter ended June 30, 2017.

"We continued to make excellent progress in driving market

adoption of our DNA technology platform in the fiscal third quarter while generating strong sales growth from our most established

revenue-generating vertical from an initial cotton order for the upcoming ginning season," said Dr. James A. Hayward, president

and CEO of Applied DNA Sciences. "In textiles, we see evidence that our technology platform is gaining momentum as brands

and retailers find it increasingly advantageous to provide assurances that the products on their shelves meet their product quality

claims. Our recently announced, more favorable licensing agreement with key cotton partner Himatsingka America, Inc. ("Himatsingka")

illustrates the increasingly strategic role our molecular tag technology is playing in supporting manufacturers' business

goals. In addition, product and customer reviews of Bed, Bath and Beyond 's Wamsutta PimaCott home fashions

- manufactured by Himatsingka and incorporating our SigNature T technology - demonstrate that authenticity is

good for business. Beyond textiles, we also secured new revenue-generating awards in government/military and diagnostics verticals

that broaden our opportunities for revenue growth."

Third Quarter Financial Highlights:

Continued Dr. Hayward, "Business development activity

during the quarter was strong with pre-commercial opportunities growing to 14 active engagements at present from nine last quarter,"

continued Dr. Hayward. "Recently concluded pilot projects, such as in Aloe vera, touch upon multiple markets, from

food and supplements to pharmaceuticals and personal care. As announced earlier this week, large-scale fertilizer tagging, offers

the opportunity for large-scale deployments that address entire commercial ecosystems, as we do in cotton. While the timing of

conversion from pilot to commercial contract is uncertain, we remain focused on expanding the basket of opportunities and on shortening

"As we look ahead, we see several areas of

revenue growth. We believe that the start of the cotton ginning season and the growing "pull" we have experienced

from brands and from new categories in our existing retail channels will help catalyze sales and improve working-capital to

cash conversion. Business activity in non-cotton textile markets is also increasing as manufacturers of products

utilizing synthetic fibers move to our technology platform to their sales advantage. Lastly, through our success in cotton we

have been able to secure annual minimum revenue commitments from customers such as Loftex Home, LLC and GHCL Limited as

licensees of CertainT , our program that integrates our commercial platforms into a licensable strategy to generate

royalty fees, in addition to revenues from the sale of DNA taggant and testing services. CertainT is today a cornerstone of

our go-to-market strategy and a key component to building a diverse, recurring revenue base. With CertainT we can

participate not only at the front end of the supply chain with the application of our molecular tags, but at the back-end of the

value chain where the cumulative value-add is the highest and we can share in the economics with brands and retailers."

Concluded Dr. Hayward, "We have been moving aggressively

to build the market for our technology platform and continue to expand our pipeline of opportunities. To help ensure that we have

the financial flexibility to capture the opportunities before us today, we have entered into binding private placement subscription

agreements with a key customer, as well as all executive officers and members of the board of directors. As we continue to build

our business, we believe our successes today will be the foundation for our sustained growth tomorrow."

Nine-Month Financial Highlights:

Recent Business and Operational

Fiscal 2017 Third Quarter Conference Call Information

The Company will hold a conference call and webcast to discuss

its fiscal 2017 third-quarter results on Thursday August 10, 2017 at 4:30 PM EST. To participate on the conference call, please

follow the instructions below. While every attempt will be made to answer investors' questions on the Q&A portion of

the call, due to the large number of expected participants, not all questions may be answered.

Dial-in and ask to be joined to the

Applied DNA Sciences earnings call.

Replay (available 1 hour following

the conclusion of the live call):

Information about Non-GAAP Financial Measures

As used herein, "GAAP" refers to accounting principles

generally accepted in the United States of America. To supplement our condensed consolidated financial statements prepared and

presented in accordance with GAAP, this earnings release includes Adjusted EBITDA, which is a non-GAAP financial measure as defined

in Rule 101 of Regulation G promulgated by the Securities and Exchange Commission. Generally, a non-GAAP financial measure is a

numerical measure of a company's historical or future performance, financial position, or cash flows that either excludes

or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented

in accordance with GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation

or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. We use this non-GAAP

financial measure for internal financial and operational decision making purposes and as a means to evaluate period-to-period comparisons

of the performance and results of operations of our core business. Our management believes that these non-GAAP financial measures

provide meaningful supplemental information regarding the performance of our business by excluding non-cash expenses that may not

be indicative of our recurring operating results. We believe this non-GAAP financial measure is useful to investors as it allows

for greater transparency with respect to key metrics used by management in its financial and operational decision making.

"EBITDA"- is defined as earnings (loss) before interest

expense, income tax expense and depreciation and amortization expense.

"Adjusted EBITDA"- is defined as EBITDA adjusted

to exclude (i) stock-based compensation and (ii) other non-cash expenses.

About Applied DNA Sciences

Sciences makes life real and safe by providing innovative, molecular-based technology solutions and services that can help

protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting,

fraud and diversion. The proprietary DNA-based "CertainTTM" Platform can be used to identify,

tag, track, and trace products, to help assure authenticity, origin, traceability and quality of products. SigNature DNA

describes the core technology ingredient that is at the heart of a family of uncopyable, security and authentication solutions

such as SigNature T and fiberTyping , targeted toward textiles and apparel, BackTrac

and DNAnet , for anti-theft and loss prevention, and digitalDNA , providing powerful track- and-trace.

All provide a forensic chain of evidence, and can be used to prosecute perpetrators. Applied DNA Sciences is also engaged in the

large-scale production of specific DNA sequences using the polymerase chain reaction.

Go to adnas.com for more information, events and to learn

more about how Applied DNA Sciences makes life real and safe. Applied DNA's Common stock is quoted on NASDAQ under the

symbol APDN, and its warrants are quoted under the symbol APDNW.

Forward-Looking Statements

The statements made by APDN in this press release may be "forward-looking"

in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe APDN's

future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties,

many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating

history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time

to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K filed on December 6, 2016, and our quarterly

reports on Form 10-Q filed on February 9, 2017, May 11, 2017, and August 10, 2017, which are or will be available at www.sec.gov.

APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances

after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay

M. Hurry, 212-838-3777, LHA, shurry@lhai.com

Media contact: Susan Forman, Dian Griesel Int'l.,

212-825-3210,sforman@dgicomm.com

Financial Tables Follow

APPLIED DNA SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS